K. Moran

Prospective study of oncogenic mutations in circulating cell-free DNA (cfDNA) using a multiplex sequencing platform for patient (pt) allocation to phase I clinical trials.

J. Bono, U. Banerji, S. Kaye, 2012 .

Phase I study of abiraterone acetate (AA) in patients (pts) with estrogen receptor- (ER) or androgen receptor (AR) -positive advanced breast carcinoma resistant to standard endocrine therapies.

M. Dowsett, A. Tutt, C. Swanton, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.

M. D. de Jonge, T. Busman, A. Krivoshik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.